Gentian Diagnostics ASA

Report Publication Announcement • Aug 23, 2017

2nd Quarter and First Half 2017 Report

2nd Quarter and First Half 2017 Report

Moss, 23 August 2017

Gentian Diagnostics AS announces its results for the second quarter

and first half year. The highlights of the quarter include:

- IVD CE marking and commercial launch for GCAL: calprotectin

in blood samples

- 81 % growth in revenue q/q and 12 % y/y

- Two more patent applications were filed

Please find the report for the second quarter and first half year

enclosed. The report will also be made available on www.gentian.no.

For further information, please contact:

Bård Sundrehagen

CEO, Gentian Diagnostics

E-mail: Bard.sundrehagen@gentian.no

Cell Phone: +47 924 14 117